Ultragenyx (RARE) CMO receives 34,674 RSUs and 59,952 stock options
Rhea-AI Filing Summary
Ultragenyx Pharmaceutical EVP and Chief Medical Officer Eric Crombez received new equity awards as part of his compensation. He was granted 34,674 shares of Common Stock in the form of Restricted Stock Units (RSUs) under the company’s 2023 Incentive Plan.
The RSUs vest over four years, with one-quarter of the underlying shares vesting on each anniversary of the grant date. Crombez also received a stock option for 59,952 shares of Common Stock at an exercise price of $24.52 per share, expiring on April 16, 2036.
The option vests with one-quarter of the shares on the first anniversary of the grant date and the remainder in equal monthly installments thereafter. Following these awards, Crombez directly holds 110,975 shares of Common Stock, including previously reported RSU-based holdings subject to vesting conditions.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 34,674 shares
Net Buy
2 txns
Insider
Crombez Eric
Role
EVP and Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 59,952 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 34,674 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 59,952 shares (Direct);
Common Stock — 110,975 shares (Direct)
Footnotes (3)
- F1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- F2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- F3. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Key Figures
RSU grant size: 34,674 shares
Stock option grant size: 59,952 shares
Option exercise price: $24.52/share
+2 more
5 metrics
RSU grant size
34,674 shares
Restricted Stock Units granted on April 16, 2026
Stock option grant size
59,952 shares
Stock Option (Right to Buy) granted on April 16, 2026
Option exercise price
$24.52/share
Conversion or exercise price for option grant
Option expiration
April 16, 2036
Expiration date of stock option grant
Common shares after grant
110,975 shares
Total Common Stock directly held after RSU award
Key Terms
Restricted Stock Units ("RSUs"), 2023 Incentive Plan, Stock Option (Right to Buy), vesting conditions, +1 more
5 terms
Restricted Stock Units ("RSUs") financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2023 Incentive Plan financial
"Award of RSUs under the Company's 2023 Incentive Plan."
Stock Option (Right to Buy) financial
"Security title listed as Stock Option (Right to Buy) for 59,952 shares."
vesting conditions financial
"Shares of common stock underlying RSUs granted are subject to certain vesting conditions."
Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.
exercise price financial
"Conversion or exercise price for the option is 24.5200 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity awards did Ultragenyx (RARE) executive Eric Crombez receive?
Eric Crombez received 34,674 Restricted Stock Units and a stock option for 59,952 shares of Common Stock. Both awards were granted under Ultragenyx’s 2023 Incentive Plan as compensation, not as open-market purchases, and are subject to multi-year vesting schedules.
How do the new RSUs granted to Ultragenyx (RARE) CMO vest?
The 34,674 RSUs vest in four equal annual installments. One-quarter of the underlying shares vests on each anniversary of the grant date, so the RSUs become fully vested on the fourth anniversary, assuming continued service throughout the vesting period.
What are the key terms of Eric Crombez’s new Ultragenyx (RARE) stock option?
The stock option covers 59,952 shares of Common Stock at an exercise price of $24.52 per share and expires on April 16, 2036. It is a compensation grant, not an open-market transaction, and is subject to a time-based vesting schedule.
How does the Ultragenyx (RARE) stock option granted to Crombez vest over time?
On the first anniversary of the grant date, one-quarter of the option shares vest. After that anniversary, one-forty-eighth of the initially subject shares vests each month, providing gradual monthly vesting following the initial one-year cliff.
Were Eric Crombez’s Ultragenyx (RARE) equity awards open-market purchases?
No. Both the 34,674 RSUs and the 59,952-share stock option were granted at a reported price of $0.00 per share. They represent compensation awards under the 2023 Incentive Plan rather than open-market buying of Ultragenyx stock.